Marshall Wace, LLP Immunic, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Immunic, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 417,883 shares of IMUX stock, worth $501,459. This represents 0.0% of its overall portfolio holdings.
Number of Shares
417,883
Previous 466,287
10.38%
Holding current value
$501,459
Previous $769,000
45.77%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding IMUX
# of Institutions
75Shares Held
51.2MCall Options Held
824KPut Options Held
354K-
Bvf Inc San Francisco, CA8.9MShares$10.7 Million0.33% of portfolio
-
Avidity Partners Management LP Dallas, TX7.97MShares$9.56 Million0.9% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.29MShares$8.75 Million0.51% of portfolio
-
Rtw Investments, LP New York, NY4.57MShares$5.48 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.92MShares$4.71 Million0.0% of portfolio
About IMMUNIC, INC.
- Ticker IMUX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,565,000
- Market Cap $36.7M
- Description
- Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...